Department of Planning and Budget 2017 Fiscal Impact Statement

1.	Bill Number: HB 1799ER							
	House of Origi	in 🗌	Introduced		Substitute		Engrossed	
	Second House		In Committee		Substitute		Enrolled	
2.	Patron: O'Bannon							
3.	Committee: Passed Both Houses							
4.	Title: Board of Pharmacy to deschedule or reschedule cannabidiol upon publication of an interim final rule.							
5.	Summary: Authorizes the Board of Pharmacy (Board) to designate, deschedule, or reschedule as a controlled substance any substance 30 days after publication in the Federal Register of a final or interim final order or rule designating such substance as a controlled substance or descheduling or rescheduling such substance. Under current law, the Board may act 120 days from such publication date. The bill also provides that a person is immune from prosecution for prescribing, administering, dispensing, or possessing pursuant to a valid prescription a substance approved as a prescription drug by the U.S. Food and Drug Administration on or after July 1, 2017, in accordance with a final or interim final rule despite the fact that such substance has not been scheduled by the Board. The immunity provided by the bill remains in effect until the earlier of (i) nine months from the date of the publication of the interim final rule or, if published within nine months of the interim final rule, the final rule or (ii) the substance is scheduled by the Board or by law.							
6.	Budget Amendment Necessary: No.							
7.	No Fiscal Impact.							
8.	Fiscal Implications: This bill would not have a fiscal impact on the Commonwealth. The Board can absorb any additional workload associated with the provisions of the bill.							
9.	Specific Agency or Political Subdivisions Affected: None.							
10.	10. Technical Amendment Necessary: No.							
11.	1. Other Comments: SB 1403, introduced by Senator Dunnavant, is a companion bill.							